-
公开(公告)号：EP3371599A1
公开(公告)日：2018-09-12
申请号：EP16790349.1
申请日：2016-11-02
发明人： KEPPLER, Oliver Till , CINATL, Jindrich , SCHNEIDER, Constanze , BALDAUF, Hanna-Mari , SCHWARZ, Sarah-Marie , SERVE, Hubert , OELLERICH, Thomas , GEISSLINGER, Gerd , HORNUNG, Veit
IPC分类号： G01N33/574
CPC分类号： G01N33/57488 , A61K35/76 , A61K35/763 , A61P35/00 , C12N15/1135 , C12N2310/141 , C12N2320/31 , C12N2710/24132 , G01N33/57426 , G01N2333/4703 , G01N2333/916 , G01N2800/52
摘要： The present invention pertains to novel treatments for cancer diseases. Treatment of cancers with nucleoside analogs (NA), which specifically inhibit rapidly dividing cells, may face preexisting NA resistance or development of resistant cancer cells resulting in poor clinical prognosis. Treatment of cancers with oncolytic herpes simplex viruses (HSV) may face preexisting resistance or development of resistant cancer cells resulting in poor clinical prognosis. The invention overcomes chemotherapy resistance or resistance to oncolytic HSV by providing methods for detecting the resistance in a cancer disease based on the expression of SAM domain and HD domain-containing protein 1 (SAMHD1) in cancer cells. Furthermore provided are treatment options addressing the chemotherapy resistance such as a combination of a SAMHD1 inhibitor with a NA. Moreover, provided are treatment options addressing the resistance to oncolytic HSV such as a combination of a SAMHD1 inhibitor or depletion of SAMHD1 with an oncolytic HSV. The invention provides new medicines and companion diagnostics supporting clinical treatment decisions.
搜索结果
1 条记录 (耗时 0.012 秒)
